title: In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.
abstract: The efficacy of a monofluorophosphate-calcium combination (MFP-Ca) in increasing lumbar bone mineral density (BMD) was assessed in a prospective double-masked study. Patients (n = 35), who had been treated for 1 year or more with prednisone-equivalent doses > or = 7 mg/day for asthma or other respiratory diseases, were randomly assigned to receive twice a day, for 2 years, either one MFP-Ca tablet [100 mg sodium monofluorophosphate (13.2 mg F-) + 500.5 mg Ca2+] or one Ca tablet (500.5 mg Ca2+). BMD was measured from L2 to L4 using a dual photon absorptiometer. The eligible patients (7 premenopausal women, 21 men), who had no previous vertebral fractures and were aged 46.5 (21-65) years, had received 18 (7.5-60) mg prednisone-equivalent/day and had a mean lumbar BMD of 0.917 +/- 0.141 g/cm2 at baseline (MO); in these 28 patients, the mean increase in lumbar BMD at final assessment was significantly greater in the MFP-Ca group (p = 0.05; Mann-Whitney). There was also a significant difference after 2 years between the two groups (p = 0.05, ANOVA) in favour of MFP-Ca, with an increase in lumbar BMD of 11% (MFP-Ca) compared with 1% (Ca); thus, with MFP-Ca, lumbar BMD increased by an average of approximately 5.5%/year. There was no statistically significant difference between the two groups in doses of corticosteroids used during the 2 study years, rate of vertebral fractures, or frequency of side-effects (which were all minor). No bone fissure was observed. Thus, the daily dose of 200 mg monofluorophosphate (26.4 mg F-) combined with 1 g Ca2+ in patients with long-term corticosteroid-treated respiratory diseases appears to be a safe and efficient way of increasing lumbar BMD, suggesting that its use should be further studied in corticosteroid-induced osteoporosis.
authors.affiliation: CHU Côte de Nacre, Caen, France.
authors.forename: G
authors.initials: G
authors.lastname: Guaydier-Souquières
authors.forename: P O
authors.initials: PO
authors.lastname: Kotzki
authors.forename: J P
authors.initials: JP
authors.lastname: Sabatier
authors.forename: B
authors.initials: B
authors.lastname: Basse-Cathalinat
authors.forename: G
authors.initials: G
authors.lastname: Loeb
mesh_terms: D015502:Absorptiometry, Photon; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000378:metabolism / Q000517:prevention & control; D002118:Calcium / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005459:Fluorides / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008159:Lumbar Vertebrae / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000008:administration & dosage* / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use*; D011446:Prospective Studies; D012140:Respiratory Tract Diseases / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D016103:Spinal Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control
chemical_list: D010710:Phosphates; C012980:fluorophosphate; D005459:Fluorides; D002118:Calcium; D011241:Prednisone